Arkema Valuation

Is V1S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of V1S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: V1S (€70.7) is trading below our estimate of fair value (€221.55)

Significantly Below Fair Value: V1S is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for V1S?

Key metric: As V1S is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for V1S. This is calculated by dividing V1S's market cap by their current earnings.
What is V1S's PE Ratio?
PE Ratio15.5x
Earnings€346.00m
Market Cap€5.37b

Price to Earnings Ratio vs Peers

How does V1S's PE Ratio compare to its peers?

The above table shows the PE ratio for V1S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.3x
EVK Evonik Industries
33.5x32.9%€7.7b
WCH Wacker Chemie
27.7x36.4%€3.4b
SY1 Symrise
36.1x13.7%€14.2b
ACT AlzChem Group
11.8x12.8%€590.2m
V1S Arkema
15.5x20.6%€5.4b

Price-To-Earnings vs Peers: V1S is good value based on its Price-To-Earnings Ratio (15.5x) compared to the peer average (27.3x).


Price to Earnings Ratio vs Industry

How does V1S's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
V1S 15.5xIndustry Avg. 16.9xNo. of Companies12PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: V1S is good value based on its Price-To-Earnings Ratio (15.5x) compared to the European Chemicals industry average (16.9x).


Price to Earnings Ratio vs Fair Ratio

What is V1S's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

V1S PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.5x
Fair PE Ratio18.1x

Price-To-Earnings vs Fair Ratio: V1S is good value based on its Price-To-Earnings Ratio (15.5x) compared to the estimated Fair Price-To-Earnings Ratio (18.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst V1S forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€70.70
€106.24
+50.3%
9.0%€125.00€87.00n/a17
Dec ’25€74.65
€107.06
+43.4%
9.0%€125.00€89.00n/a17
Nov ’25€80.35
€107.62
+33.9%
9.5%€125.00€89.00n/a17
Oct ’25€85.90
€107.85
+25.6%
9.9%€125.00€89.00n/a17
Sep ’25€83.90
€109.50
+30.5%
9.9%€127.00€92.00n/a17
Aug ’25€84.50
€110.44
+30.7%
10.3%€127.00€92.00n/a17
Jul ’25€83.40
€111.47
+33.7%
9.3%€127.00€92.00n/a17
Jun ’25€94.15
€112.00
+19.0%
8.3%€127.00€92.00n/a16
May ’25€96.50
€110.00
+14.0%
8.4%€127.00€90.00n/a16
Apr ’25€97.28
€110.44
+13.5%
9.2%€134.00€90.00n/a16
Mar ’25€94.08
€111.88
+18.9%
8.7%€134.00€90.00n/a16
Feb ’25€100.75
€112.06
+11.2%
8.8%€134.00€90.00n/a16
Jan ’25€102.25
€111.73
+9.3%
7.7%€123.00€90.00n/a15
Dec ’24€93.40
€110.07
+17.8%
8.4%€123.00€90.00€74.6515
Nov ’24€87.68
€110.40
+25.9%
8.5%€123.00€90.00€80.3515
Oct ’24€92.96
€109.60
+17.9%
8.6%€125.00€90.00€85.9015
Sep ’24€97.46
€107.25
+10.0%
11.2%€125.00€85.00€83.9016
Aug ’24€96.06
€107.00
+11.4%
11.4%€125.00€85.00€84.5016
Jul ’24€86.20
€105.68
+22.6%
11.4%€123.00€82.50€83.4017
Jun ’24€82.10
€105.19
+28.1%
12.7%€130.00€82.50€94.1518
May ’24€89.30
€106.97
+19.8%
14.8%€142.00€82.50€96.5018
Apr ’24€90.56
€107.42
+18.6%
14.7%€142.00€82.50€97.2818
Mar ’24€96.10
€103.97
+8.2%
15.9%€142.00€80.00€94.0818
Feb ’24€92.54
€102.31
+10.6%
15.6%€134.00€79.00€100.7518
Jan ’24€84.78
€102.92
+21.4%
15.6%€134.00€78.00€102.2518
Dec ’23€85.50
€103.47
+21.0%
15.7%€134.00€78.00€93.4018

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:43
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arkema S.A. is covered by 38 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Andreas HeineBarclays
James StewartBarclays